Introduction {#S1}
============

Gastrulation results in the formation of the three germ layers - ectoderm, mesoderm and endoderm. The mesoderm is a middle layer between the innermost, endoderm and the outer ectoderm. The transition from epithelial cells to mesenchymal cells marks the formation of mesoderm which is further organized into the paraxial, intermediate and lateral mesoderm ([@B90]; [@B28]). The three parts of the mesoderm are acted upon by several lineage commitment programs and differentiate into the progenitor cells that give rise to musculoskeletal, urogenital and cardiovascular structures of the body ([@B26]). Cells of these organs have the same genome, but the differences in transcriptionally active and inactive regions of genome guide the precursor cells toward different cell fates ([@B49]). The differences in genomic organization, followed by activation or silencing of genes, are the result of complex gene regulatory networks (GRNs) ([@B80]). For many years these GRNs were thought to be controlled exclusively by protein coding genes until the discovery of functional non-coding RNA transcripts (ncRNAs) which form an integrated network to shape the cellular environment during different developmental and metabolic processes ([@B56]). These ncRNAs are divided into two categories based on the transcript length---small ncRNAs (\<200 nucleotides) and long ncRNAs (\>200 nucleotides) ([@B82]). Currently, miRNAs are the best-characterized ncRNAs that are well conserved and repress the expression of target mRNA by binding to its 3′ UTR ([@B79]). On the other hand, long ncRNAs (lncRNAs) constitute a less characterized but highly diverse class of ncRNAs. lncRNAs are structurally similar to protein-coding genes as most of them are transcribed by RNA polymerase II, 5′ capped and polyadenylated at 3′ end ([@B16]). Regardless of their close similarity to the protein-coding mRNAs, lncRNAs lack the potential to code functional proteins. Although there are many lncRNAs that contain putative open reading frames and indeed some have been re-classified to protein-coding genes ([@B1]; [@B91]; [@B81]). The number of *bona-fide* lncRNAs identified in human genome is, in general, comparable to that of protein-coding genes, but only a few have been functionally characterized. Functionally, lncRNAs can either act in *cis* by regulating expression of neighboring genes, or in *trans*, regulating the expression of distant genes ([@B110]). lncRNAs regulate the gene expression by mending the 3-dimentional genome organization, mediating the binding of chromatin modifying proteins or by sequestering the bound regulatory factors or miRNAs by acting as molecular decoys or sponge ([@B87]). A summary of different mechanisms of lncRNA mediated genome regulation is represented in [Figure 1](#F1){ref-type="fig"}. A further class of lncRNAs emerging from regulatory regions of the genome such as enhancers can initiate chromatin looping by recruiting chromatin modifying factors to activate or repress transcription at distant genomic location ([@B122]). In the past decade several research groups have speculated on the functions of lncRNAs in different biological and pathological systems. More specifically, many lncRNAs have been reported to play crucial roles in the development of skeletal muscle and cardiac lineages, and connected diseases. Here, we discuss the current understanding of the roles of lncRNAs in skeletal muscle and cardiac derivatives emphasizing on their therapeutic potential in the associated pathological conditions.

![lncRNA mechanisms of action. **(A)** Guide lncRNAs activate or repress gene expression through relocalization of regulatory factors. **(B)** Scaffold lncRNAs aid in the formation of Ribonucleoprotein (RNP) complexes. **(C)** Decoy lncRNAs remove the regulatory factor bound to the genome thereby terminating its regulation. **(D)** lncRNAs sponge the miRNAs, thus inhibiting the miRNA mediated gene repression. **(E)** miRNA precursor lncRNAs function as primary miRNA precursors that are processed into mature miRNAs. **(F)** lncRNA transcription from regulatory regions of the genome initiate long range gene regulation.](fcell-07-00228-g001){#F1}

lncRNAs During Early Mesodermal Specification {#S2}
=============================================

Recent studies suggest that lncRNAs are important for mesodermal specification and further differentiation, development and function of mesodermal derivatives ([Figure 2](#F2){ref-type="fig"}). For instance, antisense RNA *Evx1as* regulates mesendodermal differentiation toward the mesoderm/posterior streak fate through *cis* regulation of Even-skipped homeobox 1 (Evx1) ([@B74]). Evx1 is a homeodomain TF that promotes mesoderm differentiation by inhibiting the endoderm/anterior streak gene *GSC* ([@B54]). The expression of the divergent lncRNA *Evx1as* was highly correlated with the expression of *Evx1*. Interestingly, *Evx1as* knockdown exhibited a higher impact on the expression of mesendoderm markers than the knockdown of Evx1, suggesting the possible trans regulation by *Evx1as* independent of Evx1 ([@B74]). lncRNA *HoxBlinc* is involved in early differentiation and is transcribed from the Homeobox B (Hoxb) locus marking the formation of Flk+ mesoderm with the potential to form hematopoietic and cardiac cells ([@B24]). As in the case of *Evx1as* and *HoxBlinc*, genomic loci of many other key developmental regulators were found to transcribe divergent lncRNAs, collectively termed as Ying Yang lncRNAs (yylncRNAs). Ying Yang lncRNAs follow tissue-specific expression patterns similar to that of their protein-coding counterparts ([@B31]). The active locus of the mesoderm specifier BRACHUARY (T) encodes *yylncT* and the expression patterns of the two were nearly identical during mesodermal commitment. The depletion of *yylncT* specifically abolished the differentiation of human embryonic stem cells (hESCs) to mesoderm without affecting the differentiation toward ectoderm and endoderm, emphasizing the mesoderm specific role of *yylncT* ([@B31]). A summary of lncRNAs regulating early mesodermal differentiation is illustrated in [Figure 2](#F2){ref-type="fig"}.

![lncRNAs expressed during early development of mesoderm and further differentiation towards skeletal muscle and cardiac lineages.](fcell-07-00228-g002){#F2}

lncRNAs Regulating Myoblast Proliferation and Muscle Development {#S3}
================================================================

During embryonic development, the paraxial mesoderm develops into segmented somites, organized into ventral sclerotome and dorsal dermomyotome which form the axial skeleton, the skeletal muscle and the dermis of the adult body, respectively ([@B21]). Myogenic progenitor cells (MPCs) are formed in the myotome and subsequently become myoblasts that proliferate and differentiate to form myotubes maturing into skeletal muscle fibers. The MPCs are also responsible for the formation of quiescent satellite cells that contribute to regeneration in adult muscles ([@B21]). Upon injury, satellite cells in the adult body get activated and become proliferative myoblasts further differentiating to form new muscle fibers. Alterations in regulatory circuitry of myogenesis leads to muscle disorders and diseases such as, hypertrophy and atrophy. This makes it advantageous to identify novel molecular regulators of myogenesis and injury induced regeneration which will aid to discern new therapeutic targets.

Before differentiating into mature myofibers, the myoblasts proliferate with the activation of cell cycle genes. lncRNA *Sirt1AS* is an antisense RNA that promotes myoblast proliferation by protecting Sirt1 mRNA---a suppressor of cell cycle inhibitors---from miR-34a mediated degradation ([@B113]). *lnc-31* also promotes proliferation by maintaining the expression of critical cell cycle genes, cyclin D1 (Ccnd1), cyclin E (Ccne1) and Cdc25a ([@B5]). *lnc-31* harbors miR-31 precursor sequence, but works independently of miR-31. Despite the poor sequence conservation, both *lnc-31* and its human homologue, *has-lnc-31*, are upregulated during proliferation antagonizing the differentiation process. Furthermore, *lnc-31* and *has-lnc-31* are abundantly expressed in Duchenne muscular dystrophy (DMD) in mice and humans ([@B5]).

Recently, lncRNA *Syisl* was reported to supress myoblast differentiation, promoting cell proliferation and fusion. *Syisl* escorts the EZH2 of PRC2 to the promoter of cell cycle inhibitor p21 and core myogenic genes like MyoG, Mck, Myh4 ([@B53]). The same study reported increase in muscle density upon *in vivo* knockout of *Syisl*. lncRNA *Syisl* presents an example of lncRNAs activated in a stage specific manner in regulation of early myogenesis. A schematic representation of lncRNAs regulating the early and late phases of myogenesis with their downstream and upstream effector targets is provided in [Figure 3](#F3){ref-type="fig"}.

![lncRNAs regulate myogenesis at different stages. During myogenesis, myoblast cells proliferate and differentiate into myocytes that fuse together to form multinucleate myotubes. The proliferative and differentiation stages of myogenesis are regulated by several lncRNAs. **(A)** lncRNAs regulating the myoblast proliferation by activating downstream cell cycle genes. **(B)** lncRNAs expression and function during cell cycle exit and differentiation to form myotubes. **(C)** MyoD activated lncRNAs regulate other myogenic factors including MyoD and MyoG to form a complex MyoD--lncRNA--miRNA--mRNA regulatory network during differentiation of myoblasts. **(D)** Examples of lncRNA expressed and regulating various skeletal muscle disorders.](fcell-07-00228-g003){#F3}

lncRNAs Regulating Myoblast Differentiation {#S4}
===========================================

Myoblast differentiation leads to the formation of multinucleate myotubes that form the mature myofiber ([@B21]). A number of stage specific factors, such as MyoD, Myf5, MyoG, and MRF4 act in coordination with epigenetic and transcriptional regulators to regulate the myoblast differentiation ([@B14]). Enhancer regions of MyoD and MyoG were shown to give rise to eRNAs (enhancer RNAs) which in turn regulate their expression. Two such examples are core enhancer eRNA (*^CE^eRNA)* and *MUNC* -- both of which are transcribed from the upstream regulatory region of MyoD ([@B88]). *^CE^eRNA* is transcribed from the core enhancer of MyoD regulating its expression in *cis* by facilitating the chromatin accessibility to RNA polymerase ll. Whereas, *MUNC* (also called as *^DRR^RNA*) is transcribed from Distal Regulatory Region (DRR) of MyoD, enhances the expression of MyoD in *cis* and of distantly located myogenic genes, MyoG and Myh3, in *trans* ([@B89]). Albeit *MUNC* overlaps the DRR of MyoD, *MUNC* acts on multiple myogenic gene promoters. Similar to eRNAs, the promoter region of mouse and human MyoG transcribes lncRNA *Myoparr* essential for cell cycle withdrawal by activating multiple myogenic factors including the neighboring TF MyoG ([@B44]). *Myoparr* regulates the interaction between MyoD coactivator Ddx17 and histone acetyl transferase and promotes denervation caused atrophy ([@B44]). The discovery of eRNAs and promoter associated RNAs highlight an additional role of regulatory regions of genome, such as enhancers, in genome regulation.

lncRNA and mRNA microarray analysis identified 997 differentially expressed lncRNAs upon MyoD knockdown in C2C12 cells ([@B37]). Gene ontology predicted that most of these lncRNAs are associated with pathways involved in muscle formation and cell cycle regulation. The study also identified *lncRNA-AK143003* to be significantly regulated by MyoD. In silencing and overexpression experiments *AK143003* acts as differentiation antagonist, but further investigation is required to assess its role and mechanism during myogenesis. This study provides a repertoire of lncRNAs in MyoD network for further validation. Another lncRNA involving MyoD in the regulatory circuitry is *linc-RAM* (Linc-RNA Activator of Myogenesis). It binds to MyoD and facilitates the assemblage of MyoD-Baf60c--Brg1 complex onto the regulatory regions of myogenic genes ([@B132]). In addition, lncRNA *SRA* acts as a coactivator for master regulator of muscle differentiation, MyoD and *SRA* Knockdown prevented proper expression of muscle genes and differentiation ([@B19]). Taken together, these lncRNAs present a second layer of regulation in the MyoD regulatory network. [Figure 3C](#F3){ref-type="fig"}, depicts an overview of MyoD regulated lncRNAs and in turn the lncRNAs modulating MyoD and other myogenic genes.

lncRNAs are known to act as guides and scaffolds by recruiting chromatin or DNA modifying complexes. *DUM* silences Dppa2, an anti-myogenic regulator, by recruiting Dnmts to CpG sites of Dppa2 promoter ([@B118]). *Dum* acts as a promyogenic factor transcriptionally induced by MyoD with highest expression during proliferation and early myogenesis. Ectopic overexpression of *DUM* improved regeneration of muscle mass ([@B118]). *lncMyoD* is another lncRNA activated by MyoD in terminal muscle differentiation suppressing the IGF2-mRNA-binding protein 2 (IMP2) mediated translation of proliferation genes ([@B34]).

The maternally imprinted lncRNA *H19* is expressed exclusively in embryonic tissues and strongly repressed after birth in all tissue types but skeletal muscles ([@B13]; [@B97]). *H19* knockdown decreased the differentiation of myoblast cells and mouse satellite cells by derepressing the mRNAs targets of miR-675-3p and miR-675-5p, encoded by *H19*, emphasizing a crucial role of *H19* during skeletal muscle differentiation ([@B25]). During myoblast differentiation, miR-675-3p downregulated the BMP pathway by targeting anti-differentiation smad1 and smad5, whereas miR-675-5p repressed the DNA replication initiation factor Cdc6 ([@B25]). Another study suggests that *H19* decrease the expression of myoblast inhibitory genes Sirt1/FoxO1, thus reinforcing the role of *H19* in muscle differentiation ([@B129]). In addition, *H19* has been shown to act as a molecular sponge for microRNAs belonging to let-7 family, preventing premature myoblast differentiation ([@B55]). More recently, a study of double mutant mice lacking MyoD and Igf2 genes elucidates a complex loop of H19 mediated Igf2 repression by MyoD in development of diaphragm muscle ([@B10]). The authors demonstrate that MyoD stabilized the interaction of CS9 mesodermal enhancer with *H19* promoter that accounts for increased expression of *H19* in the presence of MyoD. Furthermore, *H19* represses Igf2 expression in trans ([@B126]). MyoD is in turn negatively regulated due to downregulation of SRF by Igf2 encoded miR-483. Conclusively, H19-Igf2-MyoD are tightly regulated in a negative feedback loop during embryonic myogenesis ([@B98]; [@B10]). Overall, it appears that *H19* has a crucial role in myoblast differentiation by mechanistically regulating the key genes such as IGF-2, Sirt1/FoxO1, and microRNAs miR-675 and let-7 during adult as well as embryonic myogenesis.

Similar to *H19*, lncRNA *MALAT1* targets multiple factors during myogenesis. Malat1 is incessantly upregulated during the differentiation of myoblasts to myotubes and its downregulation results in cell cycle arrest in G0/G1 phase, suppressing myoblast proliferation ([@B123]). A recent study demonstrated a new mechanism of microRNA mediated degradation of *MALAT1* transcripts in myoblast nucleus by miR-181 through Ago2-dependent nuclear RNA-induced silencing complex (RISC) ([@B22]). *MALAT1* was also found to influence miR-133 mediated SRF targeting during myogenesis ([@B39]). Conclusively, these mechanistic studies provide evidence that a single lncRNA can act at different levels in GRN through multiple of modes of action.

As seen in *H19* and *MALAT1*, sponging of miRNA appears to be a common mechanism of lncRNA action in muscle differentiation. For instance, *lnc-mg* (myogenesis associated lncRNA) promoted Igf2 mediated myogenesis by titrating miR-125b ([@B138]). *lnc-mg* was enriched in skeletal muscle and its silencing caused muscle atrophy and loss of muscular endurance during exercise and its overexpression led to hypertrophy. Furthermore, its expression was dynamically induced during differentiation of muscle stem cells ([@B138]). Similarly, *linc-MD1* modulates the time of muscle differentiation by favoring the expression of MAML1 and MEF2C by sponging miR-133 and miR-135, respectively ([@B20]). In addition to sponging of miR-133, *linc-MD1* is also the host of miR-133 enabling its alternate synthesize from *linc-MD1*, controlled by a feedforward positive loop of HuR protein and *linc-MD1* ([@B60]). *linc-MD1* sponges miR-133b derepressing the expression of HuR protein which in turn physically interacts with *linc-MD1* to prevent Drosha cleavage of pri-miR-133 sequence ([@B60]).

TF Yin Yang 1 (YY1) is an important regulator of myogenesis that silences multiple genes in myoblasts by recruiting Ezh2 (Enhancer of ZesteHomologue2) ([@B18]; [@B115]). Promoter region of YY1 gives rise to *linc-YY1* exhibiting low expression in proliferating myoblasts, increased at the beginning of the myogenic program with gradual decrease in the late stages of myogenesis ([@B136]). Interestingly, YY1 follows a similar expression profile during the process. When myoblasts undergo differentiation, *linc-YY1* is activated by MyoD, which then destabilizes the YY1/PRC2 complex activating pro-differentiation genes ([@B136]). Knockdown of *linc-YY1* delayed the expression of many myogenic markers which are direct targets of YY1/PRC2, such as MyoG, MyHC, Tnni2 and a-Actin, and miR-1 and miR-29. This indicates that *linc-YY1* is a pro-myogenic factor whose knockdown in C2C12 cells delayed myogenic differentiation. Genome wide ChIP-Seq in myoblasts revealed that YY1 regulates several lincRNAs in skeletal muscle collectively called as *Yams* (YY1-associated muscle lincRNAs) ([@B72]). *Yam1* is a lncRNA regulated by YY1 and acts as an anti-myogenic factor and exerts its function in cis through regulation of miR-715 and via targeting Wnt7b expression ([@B72]). Downregulation of Wnt7b inhibits myogenic differentiation ([@B112]). Among other Yams, *Yam-3* also inhibits differentiation while, *Yam-2* and *Yam-4* facilitates early differentiation ([@B72]). These observations indicate that lncRNAs are not only regulated by key TFs but in turn regulate the function of other TFs. A list of lncRNAs regulating myogenesis is represented in [Table 1](#T1){ref-type="table"}.

###### 

List of lncRNAs regulating skeletal muscle myogenesis and their regulatory mechanisms.

  **lncRNA**   **Target**                               **Mechanism**                                                          **Function/disease relevance**                                                                                    **Species**               **References**
  ------------ ---------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------- ------------------------- ------------------------------------------
  AK143003     Unknown                                  Unknown                                                                Negative regulation of differentiation                                                                            Mouse                     [@B37]
  AK017368     Tnrc6a                                   Sponge miR-30c                                                         Promotes myoblast proliferation                                                                                   Mouse                     [@B68]
  Atrolnc1     NF-kb Murf-1                             Decoy                                                                  Promotes muscle wasting in CKD mice                                                                               Mouse                     [@B107]
  Charme       Unknown                                  Unknown                                                                Regulates robustness of skeletal and cardiac myogenesis. *In vivo* depletion in mice resulted in cardiomyopathy   Mouse                     [@B6]
  Chronos      Bmp7                                     Unknown                                                                Repressor of skeletal muscle hypertrophy                                                                          Mouse                     [@B92]
  ^CE^RNA      MyoD                                     eRNA, regulate pol II occupancy at MyoD                                Promotes myogenesis                                                                                               Mouse                     [@B88]
  DRR/MUNC     MyoD, MyoG, Myh3                         *Cis* and Trans regulation, Pol II recruitment at myogenic promoters   Promotes myogenesis And late stage regeneration                                                                   Mouse, Human              [@B88]; [@B89]
  DBT-E        Ash1l                                    Guide chromatin remodeling at D4Z4 locus                               Expressed in FSHD patients                                                                                        Human                     [@B17]
  Dum          Dppa2                                    *Cis*, recruits Dnmt 1, 3a and 3b at Dppa2 promoter                    Promotes differentiation and regeneration                                                                         Mouse                     [@B118]
  H19          Let-7, Igf2, MyoD miR-675, Sirt1/Foxo1   Cis and trans miRNA Sponge, Precursor of miRNA                         Promotes myogenic differentiation                                                                                 Mouse, Human and Cattle   [@B126]; [@B10]; [@B55]; [@B25]; [@B129]
  lnc-31       Cyclins, Cdc25a                          *Trans* acting                                                         Maintenance of myoblast proliferation, Upregulated in mdx mice and DMD patient myoblast                           Mouse, Human              [@B5]
  linc-MD1     miR-133, miR-135, Hur protein            *Cis*, miRNA sponge                                                    Controls time of muscle differentiation, Reduced in DMD patients                                                  Mouse, Human              [@B20]
  lnc-mg       miR-125b                                 miRNA sponge                                                           Promotes myogenesis, Knockout and overexpression resulted in atrophy and hypertrophy in mice, respectively        Mouse                     [@B138]
  lncMyoD      IMP2 mediated mRNA translation           Decoy                                                                  Terminal muscle differentiation                                                                                   Mouse, Human              [@B34]
  lncMUMA      miR-762                                  miRNA sponge                                                           Promotes differentiation, protects against atrophy                                                                Mouse, Human              [@B134]
  linc-RAM     Myogenic genes                           Scaffold, assembly of MyoD-Baf60c-Brg1complex                          Promotes differentiation, Impaired muscle regeneration in vivo knockout mice                                      Mouse                     [@B132]
  linc-YY1     PRC2                                     Trans, Decoy                                                           Promotes differentiation, impaired regeneration upon knockdown                                                    Mouse, Human              [@B136]
  Malat1       miR-133, Myogenic genes                  miRNA sponge, Guide Suv39h1 to myoD binding loci                       Promotes myogenesis, Improved regeneration in knockout mice                                                       Mouse, Human              [@B39]; [@B22]
  MDNCR        miR-133b                                 miRNA sponge                                                           Promote differentiation                                                                                           Cattle                    [@B64]
  Myoparr      MyoG                                     Scaffold                                                               Promotes differentiation and muscle                                                                               Mouse, Human              [@B44]
  Sirt1AS      Sirt1                                    *Cis*-acting, protects Sirt1 mRNA from miR-34a degradation             Promotes myoblast proliferation                                                                                   Mouse                     [@B113]
  SRA          MyoD                                     Unknown                                                                Promotes muscle differentiation                                                                                   Mouse                     [@B19]
  SYISL        P21, myoG, Mck                           Guides EZH2 to promoter of target genes                                Promotes myoblast proliferation and fusion                                                                        Mouse                     [@B53]
  Yam 1        Wnt7b                                    *Cis*-acting, Activates miR-715                                        Inhibits differentiation                                                                                          Mouse                     [@B72]

Therapeutic Potential of lncRNAs in Muscle Regeneration and Diseases {#S5}
====================================================================

Given the known importance of lncRNAs in skeletal muscle myogenesis, it is not surprising to know that they also regulate the process of muscle regeneration. lncRNAs such as *H19*, *DUM*, *MUNC*, *Yam1* and *lncMyoD* have been shown to regulate regeneration in cardiotoxin (CTX) model of muscle injury ([@B103]; [@B25]; [@B34]; [@B89]; [@B118]). Upon CTX mediated injury, the expression of *H19* was decreased at days 1--3, followed by increase at days 5--7 and again decreased after the formation of new myofibers at day 14. Interestingly, miR-675-3p and miR-675-5p are co-expressed with *H19* throughout the course of regeneration, making it evident that the pro-differentiation action of *H19* is mediated by microRNAs generated from it ([@B25]). While *H19* is implicated in regulating regeneration at several stages, expression of *Yam1* appears to be stage specific with highest expression at day 2 followed by a sharp reduction for the rest of the regeneration process ([@B72]). Likewise, *lncMyoD* is upregulated at days 3--5 and decreased for the remaining regeneration process ([@B34]). In contrast, *MUNC* regulates late stage muscle regeneration as its knockdown decreased the average diameter of myofiber at day 14 ([@B34]; [@B89]). Among others, the knockout of *linc-RAM* and lncRNA *IRM* in mice displayed impaired muscle regeneration, while the knockdown of *MALAT1* enhanced the regeneration ([@B22]; [@B132]; [@B106]). Paradoxically, lncRNA *LINC00961* encodes a conserved polypeptide, SPAR, downregulated during the regeneration process ([@B81]). The downregulation of SPAR activates mTORC1 important for skeletal muscle regeneration and hypertrophy. The functional importance of SPAR emphasizes that not all lncRNA-encoded peptides are translational noise and also raises concern regarding the classification of lncRNAs.

Impaired regeneration process leads to conditions like atrophy and hypertrophy characterized by muscle wasting and increase in size of muscle cells, respectively. Cachexia is a condition that involves atrophy and muscle wasting, commonly associated with chronic kidney disease (CKD) ([@B86]). lncRNA *Atrolnc-1* is elevated in atrophic muscles of mice with cachexia and its inhibition in mice with CKD attenuated muscle wasting ([@B107]). Targeting *Atrolnc-1* could possibly help ameliorate the severity of CKD. *lncMUMA* was also regulated during atrophy with minimum expression during atrophy development in hindlimb suspension (HLS) mouse model ([@B134]). A study on the role of lncRNA in age-associated atrophy identified lncRNA *Chronos* as a repressor of hypertrophic growth through negative regulation of BMP7 ([@B92]). The dysregulation of lncRNAs during atrophy and hypertrophy further strengthens their importance in development of muscle fibers.

Similar to atrophy and hypertrophy, lncRNA expression is dysregulated in muscular dystrophy. DMD is the most prevalent type of dystrophy caused by lack of functional dystrophin protein that connects muscle fibers to extracellular matrix ([@B45]). A study using tilling array designed for dystrophin locus identified novel lncRNAs with expression profiles similar to those of dystrophin gene ([@B12]). These lncRNAs have a repressive role on the full-length dystrophin isoform and their expression is inversely correlated with dystrophin long isoform in the muscle of female dystrophinopathy carriers. Among other lncRNAs, *lnc-31* is upregulated in mdx mice muscle and human DMD patients ([@B5]). On the contrary, *linc-MD1* was reduced in DMD patients ([@B20]). Facioscapulohumeral muscular dystrophy (FSHD) is another type of dystrophy characterized by wasting of facial, upper arm and shoulder girdle muscle. In 95% of FSHD cases the defect is a deletion in D4Z4 microsatellite repeat, leading to loss of repressive mark ([@B124], [@B125]). This de-repression is coordinated by a chromatin associated lncRNA *DBT-E* transcribed from D4Z4 repeat through the recruitment of Trithorax group protein at FSHD locus ([@B17]). Although, a few lncRNAs have been reported and studied in muscular dystrophies, they haven't been studied in non-dystrophic muscle diseases.

Given that lncRNAs are dysregulated in various muscular diseases, they can possibly be novel biomarkers or targets for therapeutic interventions. However, studies investigating lncRNAs in patients with muscular diseases are much languished. Genome wide association studies on different cohorts of muscular disorders may help identify lncRNA loci closely associated with genetic disorders. lncRNAs regulating myogenesis has been well explored in *in vitro* and *in vivo* mouse models, nonetheless their role in humans needs to be investigated in depth.

lncRNAs in Cardiovascular Development, Proliferation and Differentiation {#S6}
========================================================================

The heart is the first organ to be formed during mammalian embryogenesis. It consists of a multitude of cell types that are formed through complex lineage commitment programs acting upon lateral plate and paraxial mesoderm ([@B15]; [@B105]). The intricate network of signaling pathways and the core transcriptional networks in cardiovascular biology have been extensively investigated for many years. On par with the skeletal muscle development and function, lncRNA discovery has unraveled a new layer of regulation in cardiac biology. A number of studies have identified several lncRNAs crucial for cardiac commitment, differentiation and dysfunction leading to diseased conditions. Many groups have discovered new platforms to identify and catalog lncRNAs that regulate cardiac commitment and pathologies ([@B36]; [@B58]; [@B95]; [@B111]). Furthermore, the involvement of lncRNAs as therapeutic targets for cardiovascular diseases (CVDs) is beginning to be understood. In this section, we discuss the role of lncRNAs that specifies and regulates the function of cardiomyocytes, smooth muscle cells and endothelial cells and their roles in CVDs and therapeutics.

lncRNAs Regulating Early Cardiac Fate and Disease {#S7}
=================================================

The minimal regenerative capacity of cardiomyocytes makes it difficult to overcome the damage caused by cardiac diseases. Hence, novel strategies are needed that can improve the regenerative potential of the damaged myocardium. lncRNAs have emerged as novel modulators in cardiac development and regeneration in recent years. *Braveheart (Bvht)* is the first lncRNA identified in mouse cardiac commitment and its depletion in differentiating mouse embryonic stem cells (mESCs) reduced the potential to form cardiac tissue ([@B57]). More specifically, *Bvht* functions upstream of Mesp1, a master regulator of cardiac differentiation and depletion of *Bvht* decreased the expression of early cardiac cell surface markers (such as PdgfRa and Flk-1) with consistent increase in hematopoietic markers, suggesting its involvement in regulating cell fate decisions ([@B57]). However, the role of *Bvht* in hematopoietic differentiation is unclear and needs further investigation. *Bvht* lacks a human ortholog and this loss in the due course of evolution represents the species-specific differences in heart development.

lncRNA *Fendrr* with its expression restricted to the nascent lateral plate mesoderm, regulates cardiac differentiation by interacting with the PRC complex ([@B36]). *Fendrr* is imperative for the development of the heart and the body wall. Mechanistically, *Fendrr* binds to two major chromatin modifiers, PRC2 and TrxG/MLL, and recruits these complexes to the promoters of genes involved in inception and differentiation of the lateral plate mesoderm, thus regulating cardiac lineage commitment ([@B36]).

*CARMEN*, (CAR)diac (M)esoderm (E)nhancer-associated (N)oncoding RNA) is a super enhancer (SE)-associated lncRNA identified in the transcriptome of cardiac precursor cells (CPCs) obtained from the human fetal heart ([@B95], [@B94]). The *CARMEN* locus is upstream of two microRNAs known to direct differentiation toward SMC---MiR-143 and -145. *CARMEN* is a conserved lncRNA and shelters a highly active, notch-repressive, SRF/NKX2.5 bound cardiac enhancer, responsible for restricted expression of miR-143 and miR-145 during cardiac development. Notably, the mouse ortholog of *Carmen* and previously mentioned lncRNA *Bvht* are co-located in the mouse genome. Both of the lncRNAs showed maximum expression between cardiac mesoderm and cardiac precursor stages during induced cardiac differentiation of P19CL6 cells, indicative of their involvement in early cardiac specification. While *Bvht* works in *trans*, *CARMEN* functions in *cis* as well as in *trans* and both were found to be essential for maintaining the cardiac identity in neonatal cardiomyocytes ([@B57]; [@B94]). Thus, *CARMEN* represents a SE-associated lncRNA that can potentially be manipulated for initiating neocardiogenesis for treating a heart damage.

Global transcriptomic profiling of enhancer transcribed lncRNAs during ESC differentiation into cardiomyocytes in mouse and human reveal co-expression of many of lncRNAs and their predicted downstream targets ([@B95]). The human enhancer transcripts of mm-67, -85, and -130 were significantly upregulated at different time points of cardiac differentiation. More specifically, knockdown of mm-85 derived lncRNA in P19CL6 mouse embryonic carcinoma cells significantly decreased myocardin expression and upregulated mm-67 present within the myocardin gene ([@B95]). This shows the crucial role of mm-85 in regulating myocardin expression in mouse P19CL6 embryonic carcinoma cells.

The growing body of experimental evidence suggests that enhancer derived lncRNAs are important for expression of proximal target genes in cardiac development. lncRNA *Uph* (also named *Upperhand* or *Hand2os1*) is transcribed from upstream enhancer of HAND2, a regulator of heart development and reprogramming of fibroblast to cardiomyocytes ([@B2]). Knockout of *Uph* in mouse embryos resulted in the inability of the embryo to develop a right ventricular chamber and the cardiac phenotype emulated by HAND2 knockout embryos ([@B2]). More recently, deletion of *Uph* in the mouse upregulated the expression of Hand2 accompanied by the dysregulated cardiac gene program, congenital heart defects and prenatal lethality ([@B40]). While *Uph* is transcribed upstream, lncRNA *Handsdown* (*Hdn*) is located downstream of *Hand2* ([@B100]). The genetic analysis in mice demonstrated that *Hdn* is haploinsufficient and *Hdn*-heterozygous mice presented right ventricular hyperplasia with increased levels of *Hand2* ([@B100]). Thus, *Uph* and *Hdn* regulate *Hand2* expression in cis thereby playing a crucial role in cardiac development.

A study in human ESCs and zebrafish developmental models identified three lncRNAs implicated at different stages of mesoderm and cardiovascular development, namely, *TERMINATOR*, *PUNISHER* and *ALIEN* ([@B59]). These three lncRNAs are conserved from zebrafish to humans and manifest similar stage-specific expression. *TERMINATOR* is essential for early embryonic survival, pluripotency and early mesendodermal differentiation. *TERMINATOR* knockdown in zebrafish resulted in \>70% lethal embryos, and developmental arrest and severe cardiovascular defects in the surviving embryos ([@B59]). Mesodermal specification is marked by the expression of *ALIEN*. Loss of *ALIEN* resulted in mesoderm-related defects including defective vascular patterning and cardiac chamber formation, alluding toward specific role of *ALIEN* in the early developmental of the progenitor stage common to vascular and cardiomyocyte fates. Silencing of *PUNISHER* was also accompanied by severe impairments in vasculature and cardiac development and function ([@B59]). These results were extrapolated to mouse embryos and human ESCs by knockdown of the three lncRNAs followed by microarray hybridization to check for the differential expression of different genes at different stages upon knockdown of these individual lncRNAs ([@B59]). Albeit the mechanisms employed by these lncRNAs in controlling the developmental processes remains elusive.

lncRNA *H19* besides its role in early embryonic development, is also critical for late stage cardiac differentiation. During the late stage cardiac differentiation of P19CL6 mouse cells, *H19* knockdown promoted cell proliferation and inhibited apoptosis ([@B41]). *H19* curbs the expression of miR-19b, thereby increasing the expression of miR-19b target Sox-6. Thus, *H19* presents a classic example of lncRNAs having tissue specific roles and targets and provides an explanation for how lncRNAs are capable of regulating a wide variety of cellular processes at different stages in various tissues. [Table 2](#T2){ref-type="table"} consolidates the function of lncRNAs involved in cardiovascular development, homeostasis and their relevance to CVDs.

###### 

List of lncRNAs with their regulatory mechanisms and physiological impact in cardiovascular biology.

  **lncRNA**           **Target**                                        **Mode of action**                                                                      **Function**                                                                                                                                                                                                          **Species**                  **References**
  -------------------- ------------------------------------------------- --------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------- --------------------------------
  ALIEN                Unknown                                           Unknown                                                                                 Cardiovascular commitment                                                                                                                                                                                             Human, Mouse and Zebrafish   [@B59]
  ANRIL                CDKN2A/B ADIPOR1, VAMP3, C11ORF10                 Scaffold                                                                                Genetic risk factor for CAD Pro-atherogenic                                                                                                                                                                           Human                        [@B9]; [@B47]
  Apf                  Atg7                                              Sponge miR-188-3p                                                                       Controls autophagy and MI                                                                                                                                                                                             Mouse                        [@B117]
  Bvht                 Hand1, Hand2, Mesp1, Nkx2-5, Tbx20                Decoy                                                                                   Cardiac lineage commitment                                                                                                                                                                                            Mouse                        [@B57]
  Carl                 Pbh2, Bax, Caspase3, Bcl-2                        miR-539 sponging                                                                        Inhibits mitochondrial fission and apoptosis in cardiomyocyte                                                                                                                                                         Mouse, Human and Rat         [@B120]; [@B65]
  CARMEN               Gata4, mesp1, Nkx2-5, Myh6                        *Cis* and *trans* regulation SE-associated                                              Cardiac specification                                                                                                                                                                                                 Mouse Human                  [@B94]
  Chast                Plekhm1                                           *Cis*-regulation                                                                        Promotes hypertrophy                                                                                                                                                                                                  Mouse, Human                 [@B111]
  Chaer                Hypertrophy genes                                 Guides PRC2 to hypertrophic gene loci                                                   Promotes hypertrophy                                                                                                                                                                                                  Mouse, Human and Rat         [@B114]
  Chrf                 Myd88                                             Sponge miR-489                                                                          Promote hypertrophy, Elevated in HF tissues                                                                                                                                                                           Mouse, Human                 [@B119]
  Fendrr               Foxf1, Gata6, Nkx2-5, Pitx2                       Guide PRC2 and TrxG/MLL to promoters of target genes                                    Cardiovascular development                                                                                                                                                                                            Mouse, Human and Rat         [@B36]
  Ftx                  Bcl2l2                                            miR-29b-1-3p sponge                                                                     Inhibits cardiomyocyte apoptosis                                                                                                                                                                                      Mouse                        [@B70]
  GAS5                 ANNEXIN A2                                        Guide                                                                                   Supress SMC proliferation and migration                                                                                                                                                                               Human                        [@B67]
  GATA6-AS             LOXL2                                             Decoy                                                                                   Induced in ECs during hypoxia, involved in EndMT                                                                                                                                                                      Human                        [@B93]
  H19                  Sox6, MAPK, NF- kB, PTEN, VCAM-1, p21, TGF-β1     Sponge miR-19b, positively regulates miR-675, inhibition of phosphorylation of STAT3.   Proliferation and apoptosis during late stage cardiac differentiation, pro-atherogenic, promotes VSMC proliferation and restenosis, negatively regulates EC aging, prevents glucose induced EndMT                     Mouse, Human and Rat         [@B41]; [@B96]; [@B75]; [@B46]
  MALAT1               TGFBR2/SMAD3, Cyc or CCN A2, B1, B2, Cdk1, ATG7   Sponge miR-145                                                                          EndMT, Controls proliferation and migration of ECs                                                                                                                                                                    Human                        [@B84]; [@B104]
  LEENE                eNOS                                              eRNA, recruits Pol II at eNOS promoter                                                  EC homeostasis                                                                                                                                                                                                        Human, Mouse                 [@B83]
  MEG3                 PTEN, AMPK and JAK-STAT signalling                Sponge miR-21, sponge miR-9                                                             SMC proliferation and migration, supress EC proliferation and angiogenesis                                                                                                                                            Human                        [@B43]; [@B137]
  Mdrl                 miR-484                                           miR-361                                                                                 Regulates cardiomyocyte mitochondrial fission and apoptosis                                                                                                                                                           Mouse                        [@B121]
  MIAT                 VEGF                                              Sponge miR-93 and miR-150                                                               Pro-hypertrophic                                                                                                                                                                                                      Human, mouse                 [@B139]; [@B66]
  Mm67/77/85/130/132   Unknown                                           Cis-regulation, eRNAs                                                                   Cardiac development and remodelling                                                                                                                                                                                   Mouse                        [@B95]
  Mhrt                 Brg1                                              Decoy                                                                                   Prevents hypertrophy and HF                                                                                                                                                                                           Mouse, Human                 [@B38]
  MYOSLID              MYOCD, MRTF-A, TGF-β (SMAD)                       Cis and trans-regulation                                                                SMC differentiation and proliferation                                                                                                                                                                                 Human                        [@B135]
  linc-p21             P53                                               Mdm2 mediated ubiquitination of p53                                                     Repress VSMC proliferation and induce apoptosis, downregulated in atherosclerotic plaques in mice model                                                                                                               Human, Mouse                 [@B127]
  SENCR                MYOCD, *CCL5, CX3CL1, CDH5*                       Decoy                                                                                   SMC contractibility, potentiates mesodermal and endothelial commitment, regulates proliferation and migration of ECs, stabilize EC adherens junction, dysregulation associated with premature CAD and limb ischemia   Human                        [@B7]; [@B11]; [@B77]
  SMILR                HAS2, CENPF                                       *Cis*-acting                                                                            SMC proliferation, Increased expression in unstable atherosclerotic plaque and in plasma of high plasm CRP                                                                                                            Human                        [@B4]; [@B78]
  RNCR3                KLF2                                              Sponge miR-185-5p                                                                       Athero-protective                                                                                                                                                                                                     Human                        [@B102]
  ROR                  ANP and BNP                                       Sponge miR-133                                                                          Pro-hypertrophic                                                                                                                                                                                                      Mouse, Human                 [@B69]
  PANCR                PITX2                                             *Cis*-acting                                                                            Induced during early differentiation of hESCs to cardiomyocytes                                                                                                                                                       Human                        [@B35]
  PLSR4                Mfn2                                              Sponge miR-214                                                                          Anti-hypertrophic                                                                                                                                                                                                     Mouse                        [@B76]
  PUNISHER             FOXC1, TAL1                                       Guide                                                                                   Endothelial commitment                                                                                                                                                                                                Human, Mouse and Zebrafish   [@B59]
  Upperhand            Hand2                                             *Cis*-acting, eRNA                                                                      Heart development                                                                                                                                                                                                     Mouse                        [@B2]

With the expanding knowledge about the importance of lncRNAs in cell fate decisions and heart development, it is evident that they are operational in maintaining the homeostasis of cardiovascular system. High throughput RNA-sequencing has steered the identification of differentially regulated lncRNAs in cardiac pathologies. One of the common heart conditions is cardiac hypertrophy, characterized by the increase in cardiomyocyte size to compensate for inappropriate cardiac function leading to heart failure (HF). lncRNA *CHAST* was upregulated in murine and human cardiac hypertrophy and *in vivo* depletion of this lncRNA in mouse hypertrophic model prevented and reverted the condition ([@B111]). *CHAST* promotes hypertrophy by blocking autophagy and its inhibition prevented HF, thus presenting a promising target for treatment. *Chaer* is another pro-hypertrophic lncRNA which transiently interacts with PRC2 complex and attenuates hypertrophy upon its silencing in pre-stressed heart ([@B114]). Unlike *CHAST* and *Chaer*, *Mhrt* is a cardioprotective lncRNA regulated by the stress activated Brg1-Hdac-Parp chromatin repressive complex ([@B38]). Pathological stress activates Brg1 leading to aberrant gene expression including inhibition of *Mhrt.* Ultimately, this leads to cardiomyopathy and hypertrophy ([@B42]; [@B38]). *Mhrt* forms a feedback loop with chromatin remodeling factor Brg1 and its repression results in cardiomyopathy. Restoring the pre-stress levels of *Mhrt* prevented hypertrophy and heart failure. Human ortholog of lncRNA *Mhrt* is repressed in various myopathic hearts demonstrating a conserved lncRNA dependent mechanism in cardiomyopathy ([@B38]). These studies not only highlight the role of lncRNAs in diseases but also emphasize their therapeutic potential.

lncRNAs Regulating Endothelial Cell Function {#S8}
============================================

New blood vessel formation is obviously an important aspect of heart regeneration. In the adult body, perturbed vessel formation may lead to inappropriate blood supply accompanied by shortage of oxygen to the heart resulting in diseased conditions such as myocardial infarction (MI). Endothelial cells (ECs) are important for the formation of the blood vessels and EC dysfunction is one of the early steps in the development of vascular pathologies. Many studies have identified lncRNAs regulating ECs function ([Figure 4A](#F4){ref-type="fig"}) and lncRNAs differentially regulated during vascular diseases. One such example is *MALAT1* which is elevated in TGF-β1-induced endothelial-to-mesenchymal transition (EndMT) where it regulates TGFBR2 and SMAD3 by negatively regulating miR-145 ([@B128]). EndMT is a hallmark of various pathological conditions including CVDs, fibrosis and cancer and *MALAT1* regulation of EndMT is a potent target for the development of gene therapy approaches. *MALAT1* is also involved in the regulation of proliferation of ECs. *MALAT1* knockdown increased basal sprouting and migration, inhibiting the proliferation. The reduced proliferation was due to the switch of ECs from a proliferative to promigratory phenotype. In addition, there was a simultaneous increase in the expression of cell cycle inhibitors, such as p21 ([@B84]). Furthermore, *Malat1* expression was elevated in hypoxic conditions and its inhibition in a hind limb ischemia mouse model showed reduced capillary density and blood flow recovery ([@B84]). Similarly, the inhibition of lncRNA *MANTIS* also prevented the angiogenic sprouting and alignment of ECs subjected to sheer stress ([@B61]). *MANTIS* controls the angiogenesis by activating the ATPase activity of BRG1, facilitating the assemblage of RNA polymerase II onto key endothelial genes like SOX18, SMAD6, and COUP-TFII ([@B61]). Unlike *MALAT1* and *MANTIS*, overexpression of lncRNA *MEG3* suppressed EC proliferation and *in vitro* angiogenesis through negative regulation of miR-9 ([@B43]).

![lncRNAs regulating endothelial (EC) and smooth muscle cell (SMC) biology. **(A)** Examples of lncRNA regulating Endothelial cell identity, physiology and activated in hypoxic conditions. **(B)** Examples of lncRNA regulating SMC proliferation, migration, contractibility and phenotypic modulation between contractile and synthetic phenotype.](fcell-07-00228-g004){#F4}

Recently, [@B29] generated an expression atlas of human hypoxia-sensitive lncRNAs with identification of two lncRNAs---*LINC00323* and *MIR503HG*---important for sustaining EC function. The expression levels of growth factor signaling and endothelial TF GATA2 were alleviated upon silencing of these two lncRNAs, accompanied by impaired cell cycle control and blocked capillary formation ([@B29]). Another study aiming to determine hypoxia influence on lncRNA expression in HUVECs identified lncRNA *GATA6-AS* to be upregulated during hypoxia ([@B93]). *In vitro* EndMT was reduced upon *GATA6-AS* silencing along with impaired vascular sprouting and endothelial cell migration ([@B93]). Additionally, EndMT was regulated by *H19* during diabetic retinopathy where overexpression of *H19* prevented glucose mediated EndMT through regulation of TGF-β1 signaling in a Smad-independent manner ([@B109]). Moreover, *H19* was shown to regulate EC aging via negative regulation of age induced inflammatory activation ([@B46]).

lncRNA *SENCR* is important for endothelial cell commitment and function. *SENCR* overexpression substantially enhanced the mesodermal and endothelial commitment of hESC ([@B11]). In HUVECs, the upregulation of *SENCR* instigated migration, proliferation and formation of capillary-like structures. Concomitantly, silencing of *SENCR* had reducing effects on these processes. Known migratory and angiogenesis genes were downregulated upon *SENCR* silencing, with no effect on the expression of neighboring *FLI1* gene. Vascular cells derived from patients with limb ischemia and premature coronary artery disease (CAD) showed a reduced level of *SENCR* as compared to control samples ([@B11]). Recently, *SENCR* was found to be important for maintaining the membrane integrity of ECs to control the vascular permeability ([@B77]). Another important aspect of EC biology is Nitric Oxide synthesis (eNOS) that controls the vasodilation. RNA-seq and chromatin capture study identified eRNA *LEENE* enhancing the eNOS expression by recruiting RNA pol II to the eNOS promoter ([@B83]). These results suggest the importance of lncRNA in EC homeostasis and endothelial dysfunction which is one of the key triggers of vascular diseases.

lncRNA in Vascular Smooth Muscle Cell (VSMC) Function {#S9}
=====================================================

In addition to ECs, VSMC development and function is important in vascular setting. In contrast to terminally differentiated skeletal muscles, VSMCs can undergo reversible phenotypic change between contractile and synthetic phenotypes ([@B99]; [@B23]). The phenotypic diversity of VSMCs provide the necessary flexibility to the blood vessels to function under different physiological ([Figure 4B](#F4){ref-type="fig"}) and pathological conditions. In normal adult animals, VSMCs exist as highly specialized and differentiated cells with a contractile phenotype. During several vascular pathologies the differentiated VSMCs switch to a proliferative phenotype with surged synthetic activity ([@B50]). Recent studies have identified lncRNA *MALAT1* and a novel lncRNA *SMILR* as important regulators of the switch from a differentiated to a proliferative phenotype of VSMCs ([@B4]; [@B104]; [@B78]). Both were shown to promote proliferation and migration of VSMCs, but the mechanism employed and target genes are different for each. *MALAT1* knockdown facilitated the conversion of SMCs from a proliferative phenotype to a differentiated one by inhibiting autophagy ([@B104]). Mechanistically *MALAT1* was found to compete with miR-142-3p to regulate ATG7 mediated activation of autophagy that results in the conversion of VSMCs from a contractile to a proliferative state. While *MALAT1* acts in trans, *SMILR* influences cellular proliferation by regulating the expression of proximal gene HAS2, involved in atherosclerotic lesion formation ([@B4]). More specifically, *SMILR* affects the late mitotic and cytokinesis phases of cell cycle by interacting with CENPF and this *SMILR*:*CENPF* interaction is in turn regulated by Staufen1 RNA binding proteins ([@B78]). Alteration of mature VSMC from a contractile phenotype to an osteoblastic phenotype is another major aspect of VSMC biology, which leads to vascular calcification ([@B50]). The transcriptome analysis during calcification of rat VSMCs identified lncRNA *Lrrc75a-as1* as a negative regulator of vascular calcification ([@B51]).

Thirty one lncRNAs were identified from RNA-Seq in human coronary artery SMCs (HCASMC), one of which was *SENCR*, that helps maintain the normal SMC differentiated state ([@B7]). SENCR is transcribed antisense to the Friend Leukemia Integration virus1 (FLI) gene, whereas, *SENCR* knockdown had no effect on the expression of FLI1 or other neighboring genes ruling out *cis*-acting effects of *SENCR* on local gene expression. Attenuation of *SENCR* significantly reduced the expression of many SMC contractile genes, including MYOCD, at both mRNA and protein levels with significant increase in genes inducing motility ([@B7]). Collectively, these results confirm the regulatory importance of *SENCR* in human coronary artery SMC (HCASMC) differentiation and migration. A study searching for lncRNAs regulated by myocardin (MYOCD/SRF), the master switch for VSMC differentiation, identified lncRNA *MYOSLID* (MYOcardin-induced Smooth muscle Long non-coding RNA, Inducer of Differentiation) as a direct target for MYOCD/SRF and TGFβ/SMAD pathways ([@B135]). *MYOSLID* promoted VSMC differentiation and inhibited VSMC proliferation. lncRNAs regulating SMC phenotypic modulation, proliferation and migration might be used as molecular targets in therapies for diseases aggravated by vascular remodeling.

Excessive proliferation of VSMCs is a major attribute of restenosis. *In vitro* overexpression of *H19* accelerated VSMC proliferation by positively regulating miR-675, which in turn downregulates PTEN expression ([@B75]). *H19* and miR-675 were upregulated in injured arterial walls in a rat balloon injury model ([@B75]). lnc-*GAS5* is another lncRNA implicated in proliferation and migration of SMCs. Overexpression of lnc-*GAS5* inhibited the proliferation, migration and reduced apoptosis of human saphenous vein SMCs (HSVSMCs) and conversely, its silencing promoted these cellular behaviors ([@B67]). lnc-*GAS5* function is mediated through a Ca^2+^-dependent RNA binding protein, Annexin A2. Thus, low expression of lnc-*GAS5* increases proliferation and migration of HSVSMCs through AnnexinA2 facilitating in the pathogenesis of the Great Saphenous Veins. *linc-p21* is also shown to regulate SMC proliferation but its expression is downregulated during atherosclerosis ([@B127]). *linc-p21* silencing in a carotid artery injury mouse model resulted in neonatal hyperplasia due to dysregulation of multiple P53 targets ([@B127]). The angiotensin II regulated *lnc-Ang362* is a host for miR-221 and miR-222, two known miRNAs implicated in SMC proliferation ([@B63]). lnc-Ang362, miR-221 and miR-222 were increased in the lung tissues derived from pulmonary arterial hypertension (PAH) patients ([@B116]). Thus, lnc-Ang362 could be a target for treating PAH.

Diagnostic Potential of lncRNAs in CVDs {#S10}
=======================================

lncRNA with prognostic and diagnostic potential are of particular interest in the clinical arena. A Genome wide association study (GWAS) has identified chromosome 9p21 locus exhibiting the highest association with atherosclerosis ([@B47]). This risk locus encodes for lncRNA *ANRIL*, associated with atherosclerotic severity. Further investigations revealed that *ANRIL* functions in *trans*, leading to pro-atherogenic effects such as cell proliferation, increased cell adhesion and decreased apoptosis ([@B47]). The association of increased *ANRIL* level with LV dysfunction further highlights its diagnostic and prognostic importance. Similarly, another GWAS study identified that the single nucleotide polymorphism (SNP) associated with MI altered the expression of lncRNA MIAT ([@B48]).

Circulating lncRNAs can serve as biomarkers of the diseases making the diagnosis much easier. A transcriptome study identified lncRNA *LIPCAR* in the plasma of patients with heart failure as a novel biomarker which can predict heart remodeling and future death in the patients ([@B58]). Another study performed the microarray analysis in the plasma of CAD patients and reported that lncRNA *CoroMarker* as a sensitive biomarker for CAD ([@B130]). Likewise, circulating *ZFAS1* and *CDR1AS* were found to be decreased and increased in acute myocardial infarction (AMI), respectively ([@B133]). Another study reported low levels of lncRNA *GAS5* in the plasma of 30 CAD patients as compared to 30 healthy individuals ([@B131]).

Promising results for several kinds of lncRNAs were reported similarly ([@B101]). However, the authors observed difficulties in reproducibility of detection. This could be due to the low sensitivity of the conventional lncRNA detection methods. Regardless of the technical challenges the low abundancy of lncRNAs cannot undermine their reported functional importance in many instances highlighted in this review. A summary of lncRNAs as potential biomarkers and their roles in cardiac diseases is represented in [Figure 5](#F5){ref-type="fig"}.

![lncRNAs upregulated and downregulated during development of cardiac diseases and potential biomarkers. Cardiac remodeling is characterized by aberrant myocardium growth along with apoptosis and vascular remodeling leading to atherosclerosis.](fcell-07-00228-g005){#F5}

lncRNA--miRNA Interactions in Skeletal Muscle and Cardiovascular Development and Disease {#S11}
========================================================================================

The crosstalk between lncRNA--miRNA--mRNA appears to be common in different facets discussed so forth. lncRNAs inhibit the function of miRNA by binding to them in a sequence specific manner, thereby increasing the number of target mRNAs that would otherwise be suppressed by miRNAs. In this regard, comprehensive knowledge of complex lncRNA--miRNA--mRNA-networks would help develop novel RNA-based therapeutics for different diseases ([Figure 6](#F6){ref-type="fig"}).

![Overview of lncRNA--miRNA interactions in skeletal muscle and cardiovascular development and disease.](fcell-07-00228-g006){#F6}

As seen in skeletal muscle proliferation and differentiation, lncRNA *H1*9, *linc-MD1*, *lnc-mg* and *Malat1* inhibit the action of miRNAs by the sponging mechanism ([@B20]; [@B55]; [@B39]; [@B22]; [@B138]). However, lncRNAs can regulate the function of miRNAs in many different ways. For instance, lncRNA *Sirt1As* shields the miR-34a binding site on Sirt1 mRNA by binding to the transcripts ([@B113]). lncRNAs can positively regulate miRNAs by acting as precursor miRNAs as in the case of *H19* giving rise to miR-675-3p and miR-675-5p ([@B25]).

These RNA networks are not restricted to skeletal muscle but are also noticeable in cardiovascular physiology and disease. *CHRF*, *Plscr4*, *MIAT* and *ROR* were involved in miRNA mediated cardiac hypertrophy regulation. lncRNA *CHRF* triggers cardiomyocyte hypertrophy by sponging antihypertrophic miR-489, which targets Myd88 ([@B119]). Similarly, pro-hypertrophic lncRNA *MIAT* regulates anti-hypertrophic miR-93 and miR-150 ([@B139]; [@B66]). *ROR* is another hypertrophic inducer that sponges miR-133 ([@B52]). In contrast, *Plscr4* is an anti-hypertrophic lncRNA downregulating miR-214 to promote the expression of Mfn2 ([@B76]). Apoptosis and autophagy are among other pathways targeted by competing-endogenous RNAs (ceRNAs). lncRNA *CARL* has been proposed to inhibit cardiomyocyte apoptosis by sequestering miR-539, a microRNA targeting PHB2 ([@B120]), a subunit of mitochondrial membrane protein Prohibitin involved in mitochondrial homeostasis ([@B108]). Cardiomyocyte apoptosis and mitochondrial fission was also inhibited by *Mdrl* via downregulation of miR-361, counteracting the inhibition of miR-484 processing ([@B121]). lncRNA *Ftx* inhibited cardiomyocyte apoptosis by preventing miR-29b-1-5p mediated downregulation of Bcl2 ([@B70]). Likewise, *Apf* triggers autophagy by targeting Atg7 through negative regulation of miR-188-3p, an inhibitor of autophagy and myocardial infarction ([@B117]). It is interesting to note that some of the above mentioned networks are well conserved across species, suggesting the crucial roles, they have in cardiovascular biology. Hence, modulating lncRNA-miRNA-mRNA pathways could possibly be a novel strategy to suppress cardiomyocyte loss in order to protect against myocardial infarction (MI) and tailor therapies for hypertrophy. Thorough understanding of these networks in development and disease could help design better therapeutic strategies in the field of regenerative medicine.

lncRNA Therapeutics and Challenges {#S12}
==================================

There has been an increased interest in the understanding of lncRNA regulation in disease systems due to their relatively restricted expression patterns and different possible actions on cellular function(s). Given that several of these ncRNAs are dysregulated in disease conditions, modulating the levels of such lncRNAs appears to be a promising approach for therapeutics and preclinical testing. However, only a few lncRNAs have been studied in depth in relevant *ex vivo* and *in vivo* systems. Upregulation or downregulation/inhibition of lncRNA function has been the most rigorously adopted methods to understand their therapeutic potential in muscular defects and cardiovascular damage. The most commonly used gene delivery methods for RNA based therapeutics are recombinant viral systems such as adenovirus, lentivirus and adeno-associated viruses (AAVs), which are employed either to inhibit or to overexpress the mRNA, miRNA, lncRNA whole transcripts ([@B27]; [@B33]; [@B32]). The use of RNAi and antisense oligonucleotides (ASOs) present the most commonly used approaches for selective downregulation of potential lncRNAs. On the contrary, the upregulation of lncRNAs can be achieved by viral vectors that are very efficient for muscle delivery. Using the above mentioned strategies, there have been promising results toward miRNA targeting and protein coding transcripts in preclinical systems, which reached clinical trials. However, using the same delivery methods the therapeutic relevance of lncRNAs remain to be resolved.

The siRNA mediated pharmacological inhibition of cytoplasmic lncRNA *SMILR* in the *ex vivo* vein graft model significantly reduced the SMC proliferation to ameliorate the effects of vascular remodeling ([@B78]). In another approach using nanoparticle mediated transfection of siRNA against lncRNA *Chaer* directly into mouse heart decreased the cardiac hypertrophy and fibrosis and restored cardiac function ([@B114]). The inhibition level achieved by shRNAs and siRNAs are, in general, limited to the cytoplasmic lncRNA molecules. Hence, on the other hand, ASOs or GapmeRs are more suitable for nuclear lncRNAs that direct Dicer independent degradation of the target lncRNA by RNase H activity ([@B30]; [@B8]; [@B62]). The ASO technology has fewer off target effects than the small RNA mediated approach. One such example is GapmeR mediated inhibition of lncRNA *Chast* for the prevention and regression of cardiac hypertrophy *in vivo* ([@B111]). No noticeable side effects of GapmeR treatment were reported. In another study, GapmeR mediated knockdown of *Malat1* in mice muscle resulted in poor blood flow recovery and diminished capillary density ([@B84]). In addition, *in vivo* therapeutic intervention using GapmeRs targeting lncRNA *Wisper* suppressed cardiac fibrosis and improved function ([@B85]). So far, none of the antisense based lncRNA drugs have been tested in clinical studies but, this strategy has been proven to be effective and safe in a clinical trial targeting liver miR-122 with LNA-based antimiRs (mirvarsen) ([@B140]). The newer generation of ASOs provide spatial control for target delivery and with further improvements, this could be translated for lncRNA inhibition in future clinical trials.

In comparison to inhibition, overexpression of cardioprotective lncRNAs appear to be much more challenging attributing to their length and locus complexity, and sometimes incomplete knowledge of the complete sequence identity and isoform structure in the current genome annotation. In this context, the major challenge is efficient transportation of these large transcripts across the membrane barriers and determining the potential toxicity. The transgenic gene activation of the cardioprotective lncRNA *Mhrt* demonstrates the first overexpression study highlighting the translational importance of delivery of lncRNA as a drug ([@B38]). In another example, *Chast* overexpression using AAV9 (adeno-associated-virus serotype 9) viral particles promoted cardiac hypertrophy in mouse heart, suggesting it to be a crucial target for cardiac hypertrophy ([@B111]).

Advancements in RNA-sequencing technologies have led to the identification of several lncRNAs in different diseases suggesting them to be crucial targets for therapeutics. In addition, due to their distinct expression patterns they can be powerful tools for diagnostics, personalized medicine and drug development. A brief description of lncRNA-based diagnostic and therapeutic strategies is depicted in [Figure 7](#F7){ref-type="fig"}. There are several key challenges in any lncRNA-focused therapy. Firstly, the lncRNAs due to their pleiotropic actions regulate multiple targets and hence may not be target-specific and can act via more than one mechanism in a diseased state. In addition, low conservation of lncRNAs across species, is another challenge, for example a human specific lncRNA lacking conservation in mouse, makes its preclinical testing inappropriate ([@B71]). A further challenge in lncRNA therapeutics is the fact that lncRNAs are often integrated in complexes which make them inaccessible for access. Small molecules such as aptamers may help the lncRNA binding with the interacting protein complexes or induce conformational changes in the secondary or tertiary structures of lncRNA ([@B73]). This is mainly important, where the lncRNA expression does not attribute to the disease phenotype but, the lncRNA interaction with other molecules accounts for the disease. Hence, the secondary and tertiary structure of lncRNAs and their structure-function relationship should to be resolved before lncRNAs enter into therapeutics.

![lncRNA based diagnostics and therapeutic strategies. **(A)** Genome wide association studies (GWAS) help in the identification of lncRNA single nucleotide polymorphisms (SNPs) associated with disease susceptibility. These SNPs can alter the lncRNA expression in the body fluids or tissues which can serve as diagnostic or prognostic markers. In addition, improvements in RNA-sequencing technologies can lead to the identification of lncRNAs as biomarkers/disease targets in different diseases. **(B)** (i) Summarizes the potential approaches for lncRNA therapeutics, such as siRNAs that are associated with RNA-induced silencing complex (RISC) bind and cleave the target lncRNA. ASOs and LNA-GapmeRs bind to the target lncRNA in sequence specific manner leading to RNase H mediated lncRNA degradation. CRISPR/Cas9 gene editing tool can make deletion or insertion in the DNA sequence of the target lncRNA to either enhance or abrogate its expression. **(B)** (ii) Demonstrates the different lncRNA delivery strategies such as direct injections, viral particles, or via encapsulation in nanoparticles.](fcell-07-00228-g007){#F7}

The other translational limitations of lncRNA therapeutics is the lack of efficient and safe delivery systems for a controlled and targeted release. The delivery vehicle should ensure high transfection efficiency with minimal cytotoxicity but also controlled release of the lncRNA based drug during the complete process. lncRNA levels can be manipulated using viral vectors, however, the use of viral delivery methods is restricted due to the associated issues including off-target effects, activation of host immune response and the risk of insertional mutagenesis, although clinical evidence in gene therapy to date demonstrates a favorable situation. To overcome these risks, researchers believe non-viral vectors with chemical modifications and/or nanoparticles targeted to specific cell type would be advantageous in clinical trials, however, are relatively inefficient dampening down the possibility for clear efficacy signals. Finally, the use of gene editing technique such as CRISPR/Cas9 has provided both loss- or gain-of-function of lncRNA in *in vitro* and *in vivo* studies ([@B3]; [@B61]; [@B6]). Although, similar delivery issues need to be addressed with the use of gene editing tools *in vivo* too.

Conclusion {#S13}
==========

Several lncRNAs have been identified to be involved in development and pathophysiology by regulating gene expression at DNA, RNA and protein levels. Their specific expression during differentiation and disease helps qualify them as key regulators and potential therapeutic targets. However, at present the use of lncRNAs in therapeutics is in its inception. There are still certain technical issues that need to be addressed, such as the difficulties in targeting, accurate outcome predictions and discrepancies in knockdown phenotypes in *in vitro* and *in vivo*. Further improvement in detection, silencing approaches, mechanistic understanding and development of *in vivo* models would uncover the full potential of lncRNAs as diagnostic and possibly therapeutic targets.
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